About

Publications While At HealthPartners

Highlights

selected publications

Journal Article

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 

Lancet Oncology. 2018

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. 

New England Journal of Medicine. 2018

Contact

full name

J. Vansteenkiste

Quick Info

Publications

Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.

Collaboration

Co-author network

Map of science